Skip to main content
OpenTrials
Completed

NCT Number: NCT06008444

Chest Mobility, Strength, Physical Activity and Quality of Life in Parkinson's Patients With Post-COVID-19

To comparative pain intensity, chest mobility, cough strength, muscle strength, physical activity levels and quality of life in Parkinson's patients with post-COVID-19 and without post-COVID-19 was aimed in current study. Knowledge in the literature regarding this topic is still obscure.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Acute worsening and long-term sequelae of motor and non-motor symptoms have also been described in Parkinson's patients during and after SARS-CoV-2 infection, which is also known as prolonged COVID. The effects of COVID-19 on pain, chest mobility, cough strength, muscle strength, physical activity levels and quality of life in Parkinson's patients are still unclear today. For this reason, in this study, it was aimed to comparatively investigate pain, chest mobility, cough strength, muscle strength, physical activity levels and quality of life in Parkinson's patients with COVID-19 and without COVID-19 and to show the relationships between these outcome measures.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for Parkinson's patients with post-COVID-19;

  • Being diagnosed with COVID-19 at least 12 weeks ago and recovered,
  • Being over 18 years old,
  • Volunteering to participate in the research,
  • Being diagnosed with Parkinson's disease
  • Comorbid conditions (such as hypertension, diabetes) are under control
  • Being able to perceive assessments (Standardized Mini Mental Test score of 24 and above)
  • Having the ability to ambulate and walk independently
  • Being in stage 1 - 4 according to the Modified Hoehn-Yahr Scale

Inclusion criteria

for Parkinson's patients without post-COVID-19;

  • Not being diagnosed or suspected of COVID-19
  • Being over 18 years old,
  • Volunteering to participate in the research,
  • Being diagnosed with Parkinson's disease
  • Having comorbid conditions (such as hypertension, diabetes) which are under control
  • Being able to perceive assessments (Standardized Mini Mental Test score of 24 and above)
  • Having the ability to ambulate and walk independently
  • Being in stage 1 - 4 according to the Modified Hoehn-Yahr Scale

Exclusion criteria

for Parkinson's patients with and without post-COVID-19;

  • Sudden drug or dose change during the study period
  • A history of any acute/chronic orthopedic, cardiovascular, pulmonary, psychiatric or neuromuscular disease that may prevent measurements from being made.
  • Having had myocardial infarction and pulmonary embolism in the last 30 days,
  • Having a history of additional neurological (stroke, head trauma, peripheral nerve diseases, brain and spinal cord tumors, etc.) diseases other than Parkinson's disease
  • Having severe vision loss or vestibular dysfunction
  • Patients with blood pressure values above 140/90 and below 90/50 in blood pressure measurements made before the study, with arrhythmia on ECG, with a history of shortness of breath and/or palpitation

Treatment and study plan

Physical Evaluations of post-COVID-19 individuals

Other

In this research, the data of Parkinson's patients who have had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.

Physical evaluations of non-post-COVID-19 individuals

Other

In this research, the data of Parkinson's patients who have not had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.

Primary outcomes

  1. Total quality of life score evaluated by Parkinson's Disease Questionnaire (PDQ-39) questionnaire.

    Time frame: through study completion, an average of 1 year

    The status of quality of life will be evaluated using Parkinson's Disease Questionnaire (PDQ-39) questionnaire. Parkinson's Disease Questionnaire-39 (PDQ39) is a 39-item quality of life questionnaire. Evaluation for each question item ranges from 0 (no problem) to 4 (constant problem). Low scores in total indicate an improvement in people's quality of life.

Secondary outcomes

  1. Cough Strength

    Time frame: through study completion, an average of 1 year

    Cough Strength will be evaluated using a Peak Flow Meter.

  2. Daily average step count

    Time frame: through study completion, an average of 1 year

    Daily average step counts will be recorded via a pedometer everyday within 3 days after confirming enrolment. All individuals will be asked to carry their pedometers with them during the day and record to their diaries.

  3. Hand grip strength

    Time frame: through study completion, an average of 1 year

    Hand grip strength will be evaluated using a hand dynamometer.

  4. Chest mobility

    Time frame: through study completion, an average of 1 year

    Chest mobility will be evaluated using a tape measure.

  5. Cognitive status

    Time frame: through study completion, an average of 1 year

    Cognitive state will be evaluated using The mini-mental state examination (MMSE). It is an 11 question test. The highest score from the test is 30 points. Scores of 23 and lower indicate cognitive dysfunction, and scores of 24 and higher indicate normal cognitive level.

Sponsors and collaborators

Lead sponsor

Izmir Democracy University

Other

Registry information

Official study title

Chest Mobility, Cough Strength, Muscle Strength, Physical Activity and Quality of Life in Parkinson's Patients Who Have Had COVID-19

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Aug 23, 2023
Registry last updated
May 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.